Thompson Siegel & Walmsley LLC Has $6.93 Million Stake in Pfizer Inc. (NYSE:PFE)

Thompson Siegel & Walmsley LLC lowered its holdings in Pfizer Inc. (NYSE:PFE) by 1.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 188,244 shares of the biopharmaceutical company’s stock after selling 2,742 shares during the quarter. Thompson Siegel & Walmsley LLC’s holdings in Pfizer were worth $6,929,000 as of its most recent filing with the SEC.

A number of other institutional investors have also bought and sold shares of the business. NuWave Investment Management LLC raised its holdings in shares of Pfizer by 439.7% in the third quarter. NuWave Investment Management LLC now owns 1,468 shares of the biopharmaceutical company’s stock valued at $54,000 after buying an additional 1,196 shares during the last quarter. Wolff Financial Management LLC increased its position in Pfizer by 5.4% in the 3rd quarter. Wolff Financial Management LLC now owns 39,180 shares of the biopharmaceutical company’s stock valued at $1,438,000 after acquiring an additional 2,014 shares in the last quarter. Monument Capital Management raised its stake in shares of Pfizer by 0.7% in the third quarter. Monument Capital Management now owns 62,057 shares of the biopharmaceutical company’s stock worth $2,277,000 after acquiring an additional 402 shares during the last quarter. Fieldpoint Private Securities LLC lifted its position in shares of Pfizer by 5.8% during the third quarter. Fieldpoint Private Securities LLC now owns 20,420 shares of the biopharmaceutical company’s stock worth $749,000 after purchasing an additional 1,120 shares in the last quarter. Finally, Conestoga Capital Advisors LLC grew its stake in shares of Pfizer by 2.3% during the third quarter. Conestoga Capital Advisors LLC now owns 17,508 shares of the biopharmaceutical company’s stock valued at $643,000 after purchasing an additional 400 shares during the last quarter. 67.36% of the stock is currently owned by institutional investors.

Several research analysts have issued reports on the company. Barclays upped their price objective on Pfizer from $35.00 to $37.00 and gave the stock an “equal weight” rating in a report on Friday, December 4th. DZ Bank reiterated a “buy” rating and issued a $41.00 price target on shares of Pfizer in a report on Wednesday, February 3rd. Sanford C. Bernstein assumed coverage on Pfizer in a report on Tuesday, November 10th. They set a “market perform” rating and a $42.00 price objective for the company. SVB Leerink reduced their target price on shares of Pfizer from $44.00 to $40.00 and set a “market perform” rating on the stock in a research note on Wednesday, February 3rd. Finally, Royal Bank of Canada set a $42.00 price target on shares of Pfizer and gave the stock a “neutral” rating in a research note on Monday, January 4th. Eleven equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $39.38.

Shares of NYSE:PFE opened at $34.26 on Tuesday. The firm has a market cap of $190.43 billion, a price-to-earnings ratio of 22.10, a PEG ratio of 2.79 and a beta of 0.70. The company has a quick ratio of 1.13, a current ratio of 1.40 and a debt-to-equity ratio of 0.76. Pfizer Inc. has a 12 month low of $27.88 and a 12 month high of $43.08. The company’s fifty day simple moving average is $35.94 and its 200 day simple moving average is $37.10.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, February 2nd. The biopharmaceutical company reported $0.42 earnings per share for the quarter, missing the consensus estimate of $0.46 by ($0.04). The firm had revenue of $11.68 billion for the quarter, compared to analyst estimates of $11.32 billion. Pfizer had a return on equity of 24.88% and a net margin of 17.85%. The firm’s quarterly revenue was up 11.8% on a year-over-year basis. During the same period in the prior year, the company earned $0.55 earnings per share. Research analysts expect that Pfizer Inc. will post 2.89 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 5th. Shareholders of record on Friday, January 29th will be given a dividend of $0.39 per share. The ex-dividend date is Thursday, January 28th. This is a boost from Pfizer’s previous quarterly dividend of $0.38. This represents a $1.56 annualized dividend and a yield of 4.55%. Pfizer’s payout ratio is 52.88%.

Pfizer Profile

Pfizer Inc develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Sutent, Xtandi, Xalkori, Inlyta, Braftovi + Mektovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Vfend, and Zithromax brands.

See Also: What’s a Black Swan?

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.